CA2372187A1 - Ras oncogen p21 peptide vaccines - Google Patents
Ras oncogen p21 peptide vaccines Download PDFInfo
- Publication number
- CA2372187A1 CA2372187A1 CA002372187A CA2372187A CA2372187A1 CA 2372187 A1 CA2372187 A1 CA 2372187A1 CA 002372187 A CA002372187 A CA 002372187A CA 2372187 A CA2372187 A CA 2372187A CA 2372187 A1 CA2372187 A1 CA 2372187A1
- Authority
- CA
- Canada
- Prior art keywords
- peptides
- peptide
- ras
- peptide mixture
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940023041 peptide vaccine Drugs 0.000 title description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 115
- 102000016914 ras Proteins Human genes 0.000 claims abstract description 80
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 33
- 238000009566 cancer vaccine Methods 0.000 claims abstract description 4
- 229940022399 cancer vaccine Drugs 0.000 claims abstract description 4
- 230000007969 cellular immunity Effects 0.000 claims abstract description 4
- 238000011394 anticancer treatment Methods 0.000 claims abstract description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 45
- 108010014186 ras Proteins Proteins 0.000 claims description 41
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 14
- 102000043276 Oncogene Human genes 0.000 claims description 11
- 108700020796 Oncogene Proteins 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 8
- 230000005867 T cell response Effects 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 102100029974 GTPase HRas Human genes 0.000 claims 1
- 101710091881 GTPase HRas Proteins 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 102200006532 rs112445441 Human genes 0.000 abstract 1
- 102220053950 rs121913238 Human genes 0.000 abstract 1
- 102200006520 rs121913240 Human genes 0.000 abstract 1
- 102200006525 rs121913240 Human genes 0.000 abstract 1
- 102200006531 rs121913529 Human genes 0.000 abstract 1
- 102200006537 rs121913529 Human genes 0.000 abstract 1
- 102200006539 rs121913529 Human genes 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
- 102200006540 rs121913530 Human genes 0.000 abstract 1
- 102200006541 rs121913530 Human genes 0.000 abstract 1
- 102200007373 rs17851045 Human genes 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 description 36
- 230000035772 mutation Effects 0.000 description 22
- 230000028993 immune response Effects 0.000 description 18
- 229960005486 vaccine Drugs 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 12
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 12
- 201000002528 pancreatic cancer Diseases 0.000 description 12
- 208000008443 pancreatic carcinoma Diseases 0.000 description 12
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000009260 cross reactivity Effects 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 5
- 238000001516 cell proliferation assay Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 108700020978 Proto-Oncogene Proteins 0.000 description 4
- 102000052575 Proto-Oncogene Human genes 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 101150080340 tlcD gene Proteins 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- VVQIIIAZJXTLRE-QMMMGPOBSA-N (2s)-2-amino-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound CC(C)(C)OC(=O)NCCCC[C@H](N)C(O)=O VVQIIIAZJXTLRE-QMMMGPOBSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000002072 anti-mutant effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 101150009136 tlcA gene Proteins 0.000 description 1
- 101150071385 tlcB gene Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO19992102 | 1999-04-30 | ||
| NO19992102A NO309798B1 (no) | 1999-04-30 | 1999-04-30 | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| PCT/NO2000/000142 WO2000066153A1 (en) | 1999-04-30 | 2000-04-28 | RAS ONCOGEN p21 PEPTIDE VACCINES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2372187A1 true CA2372187A1 (en) | 2000-11-09 |
Family
ID=19903274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002372187A Abandoned CA2372187A1 (en) | 1999-04-30 | 2000-04-28 | Ras oncogen p21 peptide vaccines |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1173199A1 (no) |
| JP (1) | JP2002543149A (no) |
| AR (1) | AR023806A1 (no) |
| AU (1) | AU4438900A (no) |
| CA (1) | CA2372187A1 (no) |
| NO (1) | NO309798B1 (no) |
| WO (1) | WO2000066153A1 (no) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11771749B2 (en) | 2017-02-03 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | KRAS peptide vaccine compositions and method of use |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2836684B1 (fr) * | 2002-03-04 | 2004-12-17 | Inst Nat Sante Rech Med | Peptides ras mutes et leur utilisation en immunotherapie |
| US8343502B2 (en) | 2002-12-16 | 2013-01-01 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| WO2004058157A2 (en) * | 2002-12-16 | 2004-07-15 | Globeimmune, Inc. | Yeast-based vaccines as immunotherapy |
| KR20090008290A (ko) | 2006-03-27 | 2009-01-21 | 글로브이뮨 | Ｒａｓ 돌연변이와 그에 관련된 조성물 및 방법 |
| GB0821616D0 (en) | 2008-11-26 | 2008-12-31 | Lytix Biopharma As | Compounds |
| PE20161560A1 (es) * | 2009-09-03 | 2017-01-11 | Pfizer Vaccines Llc | Vacuna de pcsk9 |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| CN102060929A (zh) * | 2010-06-07 | 2011-05-18 | 夏书奇 | T细胞免疫平衡肽 |
| WO2015077717A1 (en) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status |
| US11725237B2 (en) | 2013-12-05 | 2023-08-15 | The Broad Institute Inc. | Polymorphic gene typing and somatic change detection using sequencing data |
| CA2933126A1 (en) * | 2013-12-09 | 2015-06-18 | Targovax Asa | A peptide mixture |
| AU2014368898B2 (en) | 2013-12-20 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Combination therapy with neoantigen vaccine |
| JP2017514847A (ja) * | 2014-05-06 | 2017-06-08 | タルゴバックス エーエスエー | 突然変異ｒａｓペプチド及び化学療法剤を含むペプチドワクチン |
| WO2016100975A1 (en) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Molecular biomarkers for cancer immunotherapy |
| US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
| EP3297660A2 (en) | 2015-05-20 | 2018-03-28 | The Broad Institute Inc. | Shared neoantigens |
| CA2989373A1 (en) * | 2015-06-16 | 2016-12-22 | Targovax Asa | Mutated fragments of the ras protein |
| US11549149B2 (en) | 2017-01-24 | 2023-01-10 | The Broad Institute, Inc. | Compositions and methods for detecting a mutant variant of a polynucleotide |
| US20190351039A1 (en) | 2017-02-01 | 2019-11-21 | Modernatx, Inc. | Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN114573688A (zh) * | 2018-10-19 | 2022-06-03 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
| JPWO2020145222A1 (no) * | 2019-01-07 | 2020-07-16 | ||
| IL266728B (en) * | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
| MX2022010191A (es) * | 2020-02-19 | 2022-11-14 | Aelin Therapeutics | Moleculas dirigidas a proteina ras mutante. |
| US20230287046A1 (en) * | 2020-02-19 | 2023-09-14 | Aelin Therapeutics | Molecules targeting proteins |
| WO2022219152A1 (en) * | 2021-04-16 | 2022-10-20 | Oblique Therapeutics Ab | Kras antibodies |
| WO2024112821A1 (en) * | 2022-11-22 | 2024-05-30 | Elixirgen Therapeutics, Inc. | Antigens for cancer immunotherapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957859A (en) * | 1988-02-16 | 1990-09-18 | Hoffmann-La Roche Inc. | Antibodies for transforming ras protein |
| GB9103974D0 (en) * | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| WO1997040156A1 (en) * | 1996-04-19 | 1997-10-30 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes |
| GB9620350D0 (en) * | 1996-09-30 | 1996-11-13 | Maudsley David J | Cancer vaccine |
| GB2328689A (en) * | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
-
1999
- 1999-04-30 NO NO19992102A patent/NO309798B1/no not_active IP Right Cessation
-
2000
- 2000-04-28 AR ARP000102059A patent/AR023806A1/es unknown
- 2000-04-28 JP JP2000615037A patent/JP2002543149A/ja active Pending
- 2000-04-28 EP EP00925746A patent/EP1173199A1/en not_active Withdrawn
- 2000-04-28 AU AU44389/00A patent/AU4438900A/en not_active Abandoned
- 2000-04-28 CA CA002372187A patent/CA2372187A1/en not_active Abandoned
- 2000-04-28 WO PCT/NO2000/000142 patent/WO2000066153A1/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11771749B2 (en) | 2017-02-03 | 2023-10-03 | The Medical College Of Wisconsin, Inc. | KRAS peptide vaccine compositions and method of use |
Also Published As
| Publication number | Publication date |
|---|---|
| AU4438900A (en) | 2000-11-17 |
| NO992102L (no) | 2000-10-31 |
| NO309798B1 (no) | 2001-04-02 |
| WO2000066153A1 (en) | 2000-11-09 |
| EP1173199A1 (en) | 2002-01-23 |
| AR023806A1 (es) | 2002-09-04 |
| NO992102D0 (no) | 1999-04-30 |
| JP2002543149A (ja) | 2002-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2372187A1 (en) | Ras oncogen p21 peptide vaccines | |
| EP0529023B1 (en) | Therapeutically useful peptides and peptides fragments | |
| US7192927B2 (en) | Peptides | |
| AU755736B2 (en) | Frameshift mutants of beta-amyloid precursor protein and ubiquitin-B and their use | |
| AU2007218649B2 (en) | HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same | |
| CN113891723A (zh) | 肽 | |
| EP4157335A2 (en) | A peptide cocktail | |
| JP4051602B2 (ja) | 腫瘍抗原 | |
| JP2001514190A (ja) | 細胞傷害性ｔ細胞免疫を引き出すペプチド | |
| AU2012227350B2 (en) | HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |